Unnamed: 0
int64 0
1.41M
| headline
stringlengths 3
513
| url
stringlengths 33
162
| publisher
stringlengths 3
46
| date
timestamp[s] | stock
stringlengths 1
5
|
|---|---|---|---|---|---|
1,411,921 | Silver: Lost Luster | https://www.benzinga.com/trading-ideas/short-ideas/116256/silver-lost-luster | ETF Professor | 2010-02-08T00:00:00 | ZSL |
1,411,922 | ETFs To Watch February 8, 2010 (IYR, ZSL, FXE, EWJ) | https://www.benzinga.com/trading-ideas/long-ideas/116252/etfs-to-watch-february-8-2010-iyr-zsl-fxe-ewj | ETF Professor | 2010-02-08T00:00:00 | ZSL |
1,411,923 | Benzinga's Top ETF Gainers (EDZ, ZSL, ERY, FAZ) | https://www.benzinga.com/etfs/emerging-market-etfs/111988/benzinga-s-top-etf-gainers-edz-zsl-ery-faz | Craig Jones | 2010-02-04T00:00:00 | ZSL |
1,411,924 | Benzinga's Top ETF Gainers (TYP, TZA, QID, ZSL) | https://www.benzinga.com/etfs/commodity-etfs/103792/benzinga-s-top-etf-gainers-typ-tza-qid-zsl | Craig Jones | 2010-01-28T00:00:00 | ZSL |
1,411,925 | ETFs To Watch January 27, 2010 (BRF, IEO, ZSL, XLB) | https://www.benzinga.com/trading-ideas/long-ideas/100649/etfs-to-watch-january-27-2010-brf-ieo-zsl-xlb | ETF Professor | 2010-01-27T00:00:00 | ZSL |
1,411,926 | Benzinga's Top ETF Gainers (FXP, ERX, ZSL, FAS) | https://www.benzinga.com/etfs/emerging-market-etfs/100021/benzinga-s-top-etf-gainers-fxp-erx-zsl-fas | Craig Jones | 2010-01-26T00:00:00 | ZSL |
1,411,927 | Benzinga's Top ETF Gainers (SKF, SSG, FAZ, ZSL) | https://www.benzinga.com/etfs/commodity-etfs/96688/benzinga-s-top-etf-gainers-skf-ssg-faz-zsl | Craig Jones | 2010-01-22T00:00:00 | ZSL |
1,411,928 | Benzinga's Top ETF Gainers (ZSL, FXP, EDZ, TZA) | https://www.benzinga.com/etfs/emerging-market-etfs/93675/benzinga-s-top-etf-gainers-zsl-fxp-edz-tza | Craig Jones | 2010-01-20T00:00:00 | ZSL |
1,411,929 | Benzinga's Top ETF Gainers (USD, ZSL, REC, PMNA) | https://www.benzinga.com/etfs/emerging-market-etfs/73833/benzinga-s-top-etf-gainers-usd-zsl-rec-pmna | Craig Jones | 2009-12-30T00:00:00 | ZSL |
1,411,930 | Benzinga's Top ETF Gainers (BOM, ZSL, DRV, SRS) | https://www.benzinga.com/etfs/commodity-etfs/73201/benzinga-s-top-etf-gainers-bom-zsl-drv-srs | Craig Jones | 2009-12-29T00:00:00 | ZSL |
1,411,931 | ETFs To Watch December 14, 2009 ( | https://www.benzinga.com/trading-ideas/long-ideas/60688/etfs-to-watch-december-14-2009 | ETF Professor | 2009-12-14T00:00:00 | ZSL |
1,411,932 | Benzingaâs Top ETF Gainers (FAA, GRN, BDD, ZSL, JJU) | https://www.benzinga.com/etfs/commodity-etfs/60289/benzinga%E2%80%99s-top-etf-gainers-faa-grn-bdd-zsl-jju | Eric Bosco | 2009-12-11T00:00:00 | ZSL |
1,411,933 | Benzinga's Top ETF Gainers (ZSL, SMK, EDZ, DPK) | https://www.benzinga.com/etfs/emerging-market-etfs/56846/benzinga-s-top-etf-gainers-zsl-smk-edz-dpk | Craig Jones | 2009-12-08T00:00:00 | ZSL |
1,411,934 | ETFs To Watch December 8, 2009 (IYT, SKF, EWJ, DUG, ZSL) | https://www.benzinga.com/trading-ideas/long-ideas/55313/etfs-to-watch-december-8-2009-iyt-skf-ewj-dug-zsl | ETF Professor | 2009-12-08T00:00:00 | ZSL |
1,411,935 | ETF Market Movers, December 4 (DRN, DZZ, GLL, SMN, UVT, ZSL) | https://www.benzinga.com/market-update/53297/etf-market-movers-december-4 | Eric Bosco | 2009-12-04T00:00:00 | ZSL |
1,411,936 | ETFs To Watch November 11, 2009 (XRT, OIH, SMH, FXI, IYR) | https://www.benzinga.com/trading-ideas/long-ideas/39306/etfs-to-watch-november-11-2009-xrt-oih-smh-fxi-iyr | ETF Professor | 2009-11-11T00:00:00 | ZSL |
1,411,937 | Benzinga's Daily ETF Watch (ZSL, FAZ, RFN, ERY, AGA) | https://www.benzinga.com/etfs/commodity-etfs/30050/benzinga-s-daily-etf-watch-zsl-faz-rfn-ery-aga | Craig Jones | 2009-10-26T00:00:00 | ZSL |
1,411,938 | AstraZeneca's ZS-9 Delay Highlights Broader Risk Of Pipeline-Led EPS Growth Outlook | https://www.benzinga.com/analyst-ratings/analyst-color/16/05/8040659/astrazenecas-zs-9-delay-highlights-broader-risk-of-pipel | Monica Gerson | 2016-05-27T11:31:14 | ZSPH |
1,411,939 | Analyst Sees Relypsa's Valtassa Becoming 'The Standard Of Care,' Initiates With Buy, $63 Target | https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6056537/analyst-sees-relypsas-valtassa-becoming-the-standard-of- | Monica Gerson | 2015-12-17T13:03:41 | ZSPH |
1,411,940 | EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer' | https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6023057/exclusive-relypsa-being-evaluated-by-3-4-potential-acqui | Benzinga News Desk | 2015-12-04T18:14:57 | ZSPH |
1,411,941 | Benzinga's Top Downgrades | https://www.benzinga.com/analyst-ratings/downgrades/15/11/5984465/benzingas-top-downgrades | Lisa Levin | 2015-11-18T14:26:46 | ZSPH |
1,411,942 | Citigroup Downgrades ZS Pharma to Neutral | https://www.benzinga.com/news/15/11/5984022/citigroup-downgrades-zs-pharma-to-neutral | Hal Lindon | 2015-11-18T12:46:27 | ZSPH |
1,411,943 | JP Morgan Downgraded ZS Pharma to Neutral | https://www.benzinga.com/news/15/11/5969240/jp-morgan-downgraded-zs-pharma-to-neutral | Paul Quintaro | 2015-11-09T15:59:32 | ZSPH |
1,411,944 | Benzinga's Top Downgrades | https://www.benzinga.com/analyst-ratings/downgrades/15/11/5968989/benzingas-top-downgrades | Lisa Levin | 2015-11-09T14:15:29 | ZSPH |
1,411,945 | Why These Two Firms Downgraded ZS Pharma Stock | https://www.benzinga.com/analyst-ratings/analyst-color/15/11/5968795/why-these-two-firms-downgraded-zs-pharma-stock | Monica Gerson | 2015-11-09T13:38:01 | ZSPH |
1,411,946 | Morgan Stanley Downgrades ZS Pharma to Equal-weight, Raises PT to $90.00 | https://www.benzinga.com/news/15/11/5967962/morgan-stanley-downgrades-zs-pharma-to-equal-weight-raises-pt-to-90-00 | Paul Quintaro | 2015-11-09T10:36:11 | ZSPH |
1,411,947 | Credit Suisse Downgrades ZS Pharma to Neutral, Raises PT to $90.00 | https://www.benzinga.com/news/15/11/5967947/credit-suisse-downgrades-zs-pharma-to-neutral-raises-pt-to-90-00 | Paul Quintaro | 2015-11-09T10:15:09 | ZSPH |
1,411,948 | Benzinga's Weekend M&A Chatter | https://www.benzinga.com/news/15/11/5967763/benzingas-weekend-m-a-chatter | Charles Gross | 2015-11-08T00:00:00 | ZSPH |
1,411,949 | ZS Pharma Presents Positive Interim Results from Long-Term Safety Study of ZS-9 | https://www.benzinga.com/news/15/11/5967487/zs-pharma-presents-positive-interim-results-from-long-term-safety-study-of-zs-9 | Charles Gross | 2015-11-07T00:00:00 | ZSPH |
1,411,950 | Mid-Afternoon Market Update: Sierra Wireless Drops On Downbeat Earnings; TrueCar Shares Spike Higher | https://www.benzinga.com/news/earnings/15/11/5967005/mid-afternoon-market-update-sierra-wireless-drops-on-downbeat-earnings-t | Lisa Levin | 2015-11-06T00:00:00 | ZSPH |
1,411,951 | Mid-Day Market Update: ZS Pharma Jumps On Acquisition News; Men's Wearhouse Shares Slide | https://www.benzinga.com/news/earnings/15/11/5966798/mid-day-market-update-zs-pharma-jumps-on-acquisition-news-mens-wearhouse | Lisa Levin | 2015-11-06T00:00:00 | ZSPH |
1,411,952 | Could Relypsa Be The Next Big Pharma Buyout Target? | https://www.benzinga.com/analyst-ratings/analyst-color/15/11/5966658/could-relypsa-be-the-next-big-pharma-buyout-target | Patrick Williams | 2015-11-06T00:00:00 | ZSPH |
1,411,953 | Benzinga's Volume Movers | https://www.benzinga.com/news/15/11/5966584/benzingas-volume-movers | Lisa Levin | 2015-11-06T00:00:00 | ZSPH |
1,411,954 | Stocks Hitting 52-Week Highs | https://www.benzinga.com/news/15/11/5966567/stocks-hitting-52-week-highs | Lisa Levin | 2015-11-06T00:00:00 | ZSPH |
1,411,955 | Mid-Morning Market Update: Markets Decline; Humana Earnings Beat Estimates | https://www.benzinga.com/news/earnings/15/11/5966551/mid-morning-market-update-markets-decline-humana-earnings-beat-estimates | Lisa Levin | 2015-11-06T00:00:00 | ZSPH |
1,411,956 | Morning Market Gainers | https://www.benzinga.com/news/15/11/5966505/morning-market-gainers | Lisa Levin | 2015-11-06T00:00:00 | ZSPH |
1,411,957 | Why ZS Pharma Isn't Game-Changing For AstraZeneca | https://www.benzinga.com/analyst-ratings/analyst-color/15/11/5966448/why-zs-pharma-isnt-game-changing-for-astrazeneca | Zoheb Sait | 2015-11-06T00:00:00 | ZSPH |
1,411,958 | Benzinga's Top #PreMarket Gainers | https://www.benzinga.com/news/15/11/5966246/benzingas-top-premarket-gainers | Monica Gerson | 2015-11-06T00:00:00 | ZSPH |
1,411,959 | US Stock Futures Mostly Flat; All Eyes On Jobs Report | https://www.benzinga.com/news/earnings/15/11/5966061/us-stock-futures-mostly-flat-all-eyes-on-jobs-report | Monica Gerson | 2015-11-06T00:00:00 | ZSPH |
1,411,960 | Morgan Stanley Says AstraZeneca Acquisition Of ZS Pharma is 'not game-changing', Deal Fits Well Into AstraZeneca's Portfolio | https://www.benzinga.com/analyst-ratings/analyst-color/15/11/5965895/morgan-stanley-says-astrazeneca-acquisition-of-zs-pharma | Eddie Staley | 2015-11-06T00:00:00 | ZSPH |
1,411,961 | AstraZeneca to Acquire ZS Pharma for $90/Share in Cash | https://www.benzinga.com/news/15/11/5965872/astrazeneca-to-acquire-zs-pharma-for-90share-in-cash | Charles Gross | 2015-11-06T00:00:00 | ZSPH |
1,411,962 | <font size="3" color="green">AstraZeneca to Acquire ZS Pharma for $90/Share</font> | https://www.benzinga.com/news/15/11/5965871/font-size-2-color-green-astrazeneca-to-acquire-zs-pharma-for-90share-font | Charles Gross | 2015-11-06T00:00:00 | ZSPH |
1,411,963 | Morgan Stanley Calls ZS Pharma 'Best In Class,' Upgrades Stock | https://www.benzinga.com/analyst-ratings/analyst-color/15/10/5940139/morgan-stanley-calls-zs-pharma-best-in-class-upgrades-st | Jim Swanson | 2015-10-23T00:00:00 | ZSPH |
1,411,964 | Benzinga's Top Downgrades | https://www.benzinga.com/analyst-ratings/downgrades/15/09/5852741/benzingas-top-downgrades | Lisa Levin | 2015-09-21T00:00:00 | ZSPH |
1,411,965 | Morgan Stanley Downgrades ZS Pharma to Equal-weight, Maintains $67.00 PT | https://www.benzinga.com/news/15/09/5851953/morgan-stanley-downgrades-zs-pharma-to-equal-weight-maintains-67-00-pt | Paul Quintaro | 2015-09-21T00:00:00 | ZSPH |
1,411,966 | Biotechs Coming Off One Of The Busiest Weeks In Recent Memory | https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5835943/biotechs-coming-off-one-of-the-busiest-weeks-in-recent-m | Jayson Derrick | 2015-09-14T00:00:00 | ZSPH |
1,411,967 | Benzinga's Volume Movers | https://www.benzinga.com/news/15/09/5832337/benzingas-volume-movers | Lisa Levin | 2015-09-11T00:00:00 | ZSPH |
1,411,968 | Morning Market Gainers | https://www.benzinga.com/news/15/09/5832178/morning-market-gainers | Lisa Levin | 2015-09-11T00:00:00 | ZSPH |
1,411,969 | Benzinga's Top #PreMarket Gainers | https://www.benzinga.com/news/15/09/5831733/benzingas-top-premarket-gainers | Monica Gerson | 2015-09-11T00:00:00 | ZSPH |
1,411,970 | Benzinga's M&A Chatter for Thursday September 10, 2015 | https://www.benzinga.com/news/15/09/5830900/benzingas-m-a-chatter-for-thursday-september-10-2015 | Charles Gross | 2015-09-10T00:00:00 | ZSPH |
1,411,971 | ZS Pharma Resumes Trading; Now Up 7% After-Hours | https://www.benzinga.com/news/15/09/5830713/zs-pharma-resumes-trading-now-up-7-after-hours | Charles Gross | 2015-09-10T00:00:00 | ZSPH |
1,411,972 | Shares of ZS Pharma to Resume Trade at 5:50 p.m. EDT | https://www.benzinga.com/news/15/09/5830645/shares-of-zs-pharma-to-resume-trade-at-5-50-p-m-edt | Paul Quintaro | 2015-09-10T00:00:00 | ZSPH |
1,411,973 | ZS Pharma Confirms Preliminary Discussion With Actelion Regarding Strategic Transaction | https://www.benzinga.com/news/15/09/5830639/zs-pharma-confirms-preliminary-discussion-with-actelion-regarding-strategic-trans | Hal Lindon | 2015-09-10T00:00:00 | ZSPH |
1,411,974 | Actelion Pharma Issues Statement Related to ZS Pharma, Confirms Initiation of Prelim. Discussions with Co. | https://www.benzinga.com/news/15/09/5830610/actelion-pharma-issues-statement-related-to-zs-pharma-confirms-initiation-of-prel | Paul Quintaro | 2015-09-10T00:00:00 | ZSPH |
1,411,975 | ZS Pharma. Halted News Pending | https://www.benzinga.com/news/15/09/5830411/zs-pharma-halted-news-pending | Hal Lindon | 2015-09-10T00:00:00 | ZSPH |
1,411,976 | Shares of ZS Pharma Halted News Pending | https://www.benzinga.com/news/15/09/5830380/shares-of-zs-pharma-halted-news-pending | Paul Quintaro | 2015-09-10T00:00:00 | ZSPH |
1,411,977 | ZS Pharma Declines Comment on Rumor of Approach by Actelion | https://www.benzinga.com/news/15/09/5830305/zs-pharma-declines-comment-on-rumor-of-approach-by-actelion | Charles Gross | 2015-09-10T00:00:00 | ZSPH |
1,411,978 | Shares of ZS Pharma Resume Following Circuit Breaker Halt, Stock Now Up 46% for Session, Up ~26% Since Report | https://www.benzinga.com/movers/15/09/5829848/shares-of-zs-pharma-resume-following-circuit-breaker-halt-stock-now-up-46-for-s | Paul Quintaro | 2015-09-10T00:00:00 | ZSPH |
1,411,979 | Shares of ZS Pharma Spike ~10% Higher Following Bloomberg Reporting Suggesting Actelion Has Approached Co. Related to Potential Purchase | https://www.benzinga.com/news/15/09/5829847/shares-of-zs-pharma-spike-10-higher-following-bloomberg-reporting-suggesting-acte | Paul Quintaro | 2015-09-10T00:00:00 | ZSPH |
1,411,980 | ZS Pharma Says Still Scheduled to Present at Morgan Stanley Global Healthcare Unplugged Conference on September 17, 2015 | https://www.benzinga.com/news/15/09/5829439/zs-pharma-says-still-scheduled-to-present-at-morgan-stanley-global-healthcare-unp | Charles Gross | 2015-09-10T00:00:00 | ZSPH |
1,411,981 | Benzinga's Volume Movers | https://www.benzinga.com/news/15/09/5828977/benzingas-volume-movers | Lisa Levin | 2015-09-10T00:00:00 | ZSPH |
1,411,982 | Credit Suisse: Top 11 Small-Cap Growth Stocks | https://www.benzinga.com/analyst-ratings/analyst-color/15/08/5764182/credit-suisse-top-11-small-cap-growth-stocks | Wayne Duggan | 2015-08-14T00:00:00 | ZSPH |
1,411,983 | ZS Pharma's Main Competitor Could Face Headwinds Soon, So Go Overweight ZSPH: Morgan Stanley | https://www.benzinga.com/analyst-ratings/analyst-color/15/08/5763053/zs-pharmas-main-competitor-could-face-headwinds-soon-so- | Monica Gerson | 2015-08-13T00:00:00 | ZSPH |
1,411,984 | Morgan Stanley Initiates Coverage on ZS Pharma at Overweight, Announces $67.00 PT | https://www.benzinga.com/news/15/08/5762275/morgan-stanley-initiates-coverage-on-zs-pharma-at-overweight-announces-67-00-pt | Paul Quintaro | 2015-08-13T00:00:00 | ZSPH |
1,411,985 | ZS Pharma Reports Q2 Loss $1.30 Vs Est Loss $0.85 | https://www.benzinga.com/news/earnings/15/08/5745437/zs-pharma-reports-q2-loss-1-30-vs-est-loss-0-85 | Eddie Staley | 2015-08-06T00:00:00 | ZSPH |
1,411,986 | ZS Pharma Reports FDA Acceptance of ZS-9 New Drug Application | https://www.benzinga.com/news/15/07/5716178/zs-pharma-reports-fda-acceptance-of-zs-9-new-drug-application | Hal Lindon | 2015-07-29T00:00:00 | ZSPH |
1,411,987 | Option Alert: ZS Pharma Jul $65 Call; 2137 Contracts @Ask @$0.60 | https://www.benzinga.com/markets/options/15/07/5666898/option-alert-zs-pharma-jul-65-call-2137-contracts-ask-0-60 | Charles Gross | 2015-07-13T00:00:00 | ZSPH |
1,411,988 | ZS Pharma Appoints Jeffrey Farro CFO | https://www.benzinga.com/news/15/06/5597717/zs-pharma-appoints-jeffrey-farro-cfo | Hal Lindon | 2015-06-16T00:00:00 | ZSPH |
1,411,989 | 2 Small Cap Pharma Stocks Credit Suisse Loves | https://www.benzinga.com/analyst-ratings/analyst-color/15/05/5543642/2-small-cap-pharma-stocks-credit-suisse-loves | Mark Meadows | 2015-05-27T00:00:00 | ZSPH |
1,411,990 | ZS Pharma Submits New Drug Application to U.S. Food and Drug Administration for ZS-9 Hyperkalemia Treatment | https://www.benzinga.com/news/15/05/5541066/zs-pharma-submits-new-drug-application-to-u-s-food-and-drug-administration-for-zs | Hal Lindon | 2015-05-26T00:00:00 | ZSPH |
1,411,991 | ZS Pharma Prices ~4.015M Share Offering @$46.25/Share | https://www.benzinga.com/news/15/03/5354509/zs-pharma-prices-4-015m-share-offering-46-25share | Charles Gross | 2015-03-25T00:00:00 | ZSPH |
1,411,992 | ZS Pharma Announces 3.3M Stock Offering | https://www.benzinga.com/news/15/03/5349584/zs-pharma-announces-3-3m-offering | Hal Lindon | 2015-03-23T00:00:00 | ZSPH |
1,411,993 | Amended S-1 from ZS Pharma Shows Registration for 3.3M Share Offering | https://www.benzinga.com/news/15/03/5349568/amended-s-1-from-zs-pharma-shows-registration-for-3-3m-share-offering | Paul Quintaro | 2015-03-23T00:00:00 | ZSPH |
1,411,994 | ZS Pharma To Present Phase 3 Trial Data Of ZS-9 On March 25-29 2015 In Dallas, TX | https://www.benzinga.com/news/15/03/5340206/zs-pharma-to-present-phase-3-trial-data-of-zs-9-on-march-25-29-2015-in-dallas-tx | Eddie Staley | 2015-03-19T00:00:00 | ZSPH |
1,411,995 | S-1 from ZS Pharma Shows Registration to Sell ~$150M in Shares | https://www.benzinga.com/news/15/03/5326296/s-1-from-zs-pharma-shows-registration-to-sell-150m-in-shares | Paul Quintaro | 2015-03-13T00:00:00 | ZSPH |
1,411,996 | ZS Pharma Reports Q4 EPS -$0.98 Vs Est -$0.75 | https://www.benzinga.com/news/earnings/15/03/5324306/zs-pharma-reports-q4-eps-0-98-vs-est-0-75 | Eddie Staley | 2015-03-13T00:00:00 | ZSPH |
1,411,997 | ZS Pharma Names Jose Menoyo SVP, Medical Affairs; Stuart Turner Joins Company As Executive Director, Medical Affairs Head Of MSL Team | https://www.benzinga.com/news/15/02/5255218/zs-pharma-names-jose-menoyo-svp-medical-affairs-stuart-turner-joins-company-as-ex | Hal Lindon | 2015-02-19T00:00:00 | ZSPH |
1,411,998 | Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2 | https://www.benzinga.com/trading-ideas/long-ideas/15/01/5136446/biotechs-presenting-at-the-j-p-morgan-healthcare-conference-d | Kyle Dennis | 2015-01-12T00:00:00 | ZSPH |
1,411,999 | ZS Pharma Announces Publication Of Results From Phase 3 Study Of ZS-9 In Patients With Hyperkalemia In The New England Journal Of Medicine | https://www.benzinga.com/news/14/11/5030285/zs-pharma-announces-publication-of-results-from-phase-3-study-of-zs-9-in-patients | Eddie Staley | 2014-11-21T00:00:00 | ZSPH |
1,412,000 | ZS Pharma Presents Positive Results From HARMONIZE, A Second Phase 3 Clinical Trial Of ZS-9 In Patients With Hyperkalemia | https://www.benzinga.com/news/14/11/5014247/zs-pharma-presents-positive-results-from-harmonize-a-second-phase-3-clinical-tria | Eddie Staley | 2014-11-17T00:00:00 | ZSPH |
1,412,001 | ZS Pharma Reports Q3 EPS of $(0.81) vs $(0.74) Est; Revenue of $0.00 | https://www.benzinga.com/news/earnings/14/11/4997344/zs-pharma-reports-q3-eps-of-0-81-vs-0-74-est-revenue-of-0-00 | Hal Lindon | 2014-11-10T00:00:00 | ZSPH |
1,412,002 | ZS Pharma Reports Q3 EPS of $(0.81) vs $(0.74) Est; Revenue of $0.00 | https://www.benzinga.com/news/earnings/14/11/4997343/zs-pharma-reports-q3-eps-of-0-81-vs-0-74-est-revenue-of-0-00 | Hal Lindon | 2014-11-10T00:00:00 | ZSPH |
1,412,003 | ZS Pharma Announces Late Breaking Presentation of Phase 3 HARMONIZE Trial Results in Patients With Hyperkalemia at AHA Annual Meeting | https://www.benzinga.com/news/14/11/4987360/zs-pharma-announces-late-breaking-presentation-of-phase-3-harmonize-trial-results | Charles Gross | 2014-11-06T00:00:00 | ZSPH |
1,412,004 | ZS Pharma Announces Multiple Presentations From ZS003, a Phase 3 Trial of ZS-9, at the American Society of Nephrology Annual Meeting | https://www.benzinga.com/news/14/10/4968753/zs-pharma-announces-multiple-presentations-from-zs003-a-phase-3-trial-of-zs-9-at- | Hal Lindon | 2014-10-30T00:00:00 | ZSPH |
1,412,005 | ZS Pharma Offers Top-Line Results from HARMONIZE (ZS004) Phase 3 Trial of ZS-9 | https://www.benzinga.com/news/14/09/4870916/zs-pharma-offers-top-line-results-from-harmonize-zs004-phase-3-trial-of-zs-9 | Paul Quintaro | 2014-09-23T00:00:00 | ZSPH |
1,412,006 | ZS Pharma Presents New Data From ZS003 Phase 3 Trial Demonstrating Results Were Significantly Different from Placebo | https://www.benzinga.com/news/14/09/4851080/zs-pharma-presents-new-data-from-zs003-phase-3-trial-demonstrating-results-were-s | Charles Gross | 2014-09-15T00:00:00 | ZSPH |
1,412,007 | ZS Pharma To Present Phase 3 Trail Data Sept. 15 | https://www.benzinga.com/news/14/09/4842408/zs-pharma-to-present-phase-3-trail-data-sept-15 | Hal Lindon | 2014-09-11T00:00:00 | ZSPH |
1,412,008 | ZS Pharma Reports Q2 EPS of $(4.72) | https://www.benzinga.com/news/earnings/14/08/4782385/zs-pharma-reports-q2-eps-of-4-72 | Hal Lindon | 2014-08-14T00:00:00 | ZSPH |
1,412,009 | ZS Pharma Closes Patient Enrollment in Trial of ZS004, Sees Top-Line Results in Late Q3, Early Q4 | https://www.benzinga.com/news/14/07/4700420/zs-pharma-closes-patient-enrollment-in-trial-of-zs004-sees-top-line-results-in-la | Paul Quintaro | 2014-07-14T00:00:00 | ZSPH |
1,412,010 | William Blair Initiates Coverage on ZS Pharma at Outperform, Announces $75.00 PT | https://www.benzinga.com/news/14/07/4699378/william-blair-initiates-coverage-on-zs-pharma-at-outperform-announces-75-00-pt | Paul Quintaro | 2014-07-14T00:00:00 | ZSPH |
1,412,011 | Morning Market Movers | https://www.benzinga.com/news/14/07/4699370/morning-market-movers | Lisa Levin | 2014-07-14T00:00:00 | ZSPH |
1,412,012 | Benzinga's Top Initiations | https://www.benzinga.com/analyst-ratings/initiation/14/07/4699047/benzingas-top-initiations | Lisa Levin | 2014-07-14T00:00:00 | ZSPH |
1,412,013 | JP Morgan Initiates ZS Pharma At Overweight | https://www.benzinga.com/analyst-ratings/initiation/14/07/4698722/jp-morgan-initiates-zs-pharma-at-overweight | Monica Gerson | 2014-07-14T00:00:00 | ZSPH |
1,412,014 | BMO Capital Initiates Coverage on ZS Pharma at Outperform, Announces $38.00 PT | https://www.benzinga.com/news/14/07/4698507/bmo-capital-initiates-coverage-on-zs-pharma-at-outperform-announces-38-00-pt | Paul Quintaro | 2014-07-14T00:00:00 | ZSPH |
1,412,015 | JP Morgan Initiates Coverage on ZS Pharma at Overweight, Announces $43.00 PT | https://www.benzinga.com/news/14/07/4698506/jp-morgan-initiates-coverage-on-zs-pharma-at-overweight-announces-43-00-pt | Paul Quintaro | 2014-07-14T00:00:00 | ZSPH |
1,412,016 | ZS Pharma Starts Phase 3 Enrollment | https://www.benzinga.com/news/14/06/4663088/zs-pharma-starts-phase-3-enrollment | Paul Quintaro | 2014-06-26T00:00:00 | ZSPH |
1,412,017 | ZS Pharma Director Nohra Buys 200,000 Shares @$18.00/Share -Form 4 | https://www.benzinga.com/news/14/06/4660346/zs-pharma-director-nohra-buys-200-000-shares-18-00share-form-4 | Charles Gross | 2014-06-25T00:00:00 | ZSPH |
1,412,018 | IPO Lookout: IPOs Up Double Digits On The Week | https://www.benzinga.com/news/14/06/4649630/ipo-lookout-ipos-up-double-digits-on-the-week | Charles Enser | 2014-06-20T00:00:00 | ZSPH |
1,412,019 | Shares of ZS Pharma Open for Trade at $27.21/Share, Priced at $18 | https://www.benzinga.com/news/14/06/4643108/shares-of-zs-pharma-open-for-trade-at-27-21share-priced-at-18 | Paul Quintaro | 2014-06-18T00:00:00 | ZSPH |
1,412,020 | Waiting on 6IPOs Wednesday Morning | https://www.benzinga.com/news/14/06/4642603/waiting-on-6ipos-wednesday-morning | Hal Lindon | 2014-06-18T00:00:00 | ZSPH |